Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending 30 June 2017, prepared in accordance with IFRS as endorsed by the European Union. The full interim financial report is available on Celyad's website in the Investors section. The half year 2017 consolidated financial statements were subject to a limited review by the company's statutory auditors.

Click here to listen to the conference call

Celyad SA published this content on 30 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 30 August 2017 21:47:07 UTC.

Original documenthttps://www.celyad.com/en/news/conference-call-celyad-first-half-2017

Public permalinkhttp://www.publicnow.com/view/78CAD7EDE59FA0A52B8555E6CBFA22FFC15176DE